Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by experimental HIV-1 vaccines. When these antibodies do occur, it is important to be able to isolate and characterize them to provide clues for vaccine design. CAP206 is a South African subtype C HIV-1-infected individual previously shown to have broadly neutralizing plasma antibodies targeting the envelope gp41 distal membrane proximal external region (MPER). We have now used a fluoresceinated peptide tetramer antigen with specific cell sorting to isolate a human neutralizing monoclonal antibody (mAb) against the HIV-1 envelope gp41 MPER. The isolated recombinant mAb, CAP206-CH12, utilized a portion of the distal MPER (HXB2 amino acid residues, 673...
SummaryAlthough rarely elicited during natural human infection, the most broadly neutralizing antibo...
The isolation of human monoclonal antibodies (mAbs) that neutralize a broad spectrum of primary HIV-...
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these anti...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
The C3-V4 region is a major target of autologous neutralizing antibodies in HIV-1 subtype C infectio...
Includes bibliographical references.Inducing broadly neutralizing antibodies targeting the HIV-1 env...
A comprehensive understanding of the regions on HIV-1 envelope trimers targeted by broadly neutraliz...
A thesis submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,...
We identified three cross-neutralizing plasma samples with high-titer anti-membrane proximal externa...
The membrane proximal external region (MPER) of the HIV-1 glycoprotein gp41 is targeted by the broad...
The membrane proximal external region (MPER) of the HIV-1 glycoprotein gp41 is targeted by the broad...
The C3-V4 region is a major target of autologous neutralizing antibodies in HIV-1 subtype C infectio...
AbstractThe membrane-proximal external region (MPER) of gp41 is considered as a prime target for the...
SummaryAlthough rarely elicited during natural human infection, the most broadly neutralizing antibo...
The isolation of human monoclonal antibodies (mAbs) that neutralize a broad spectrum of primary HIV-...
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these anti...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
The C3-V4 region is a major target of autologous neutralizing antibodies in HIV-1 subtype C infectio...
Includes bibliographical references.Inducing broadly neutralizing antibodies targeting the HIV-1 env...
A comprehensive understanding of the regions on HIV-1 envelope trimers targeted by broadly neutraliz...
A thesis submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,...
We identified three cross-neutralizing plasma samples with high-titer anti-membrane proximal externa...
The membrane proximal external region (MPER) of the HIV-1 glycoprotein gp41 is targeted by the broad...
The membrane proximal external region (MPER) of the HIV-1 glycoprotein gp41 is targeted by the broad...
The C3-V4 region is a major target of autologous neutralizing antibodies in HIV-1 subtype C infectio...
AbstractThe membrane-proximal external region (MPER) of gp41 is considered as a prime target for the...
SummaryAlthough rarely elicited during natural human infection, the most broadly neutralizing antibo...
The isolation of human monoclonal antibodies (mAbs) that neutralize a broad spectrum of primary HIV-...
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these anti...